rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Genprex, Inc.

GNPX · Nasdaq

Health CareBiotechnologyNot moving yet

GNPX stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 84.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$44
Officials’ trades on record
4
Institutions holding
26 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$42$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

4 disclosed lines: House 4, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Tim Moore House: U.S. House ClerkNC14bought$1k–$15k5 Feb 2026filed 20 Feb 2026
Tim Moore House: U.S. House ClerkNC14bought$1k–$15k18 Dec 2025filed 7 Jan 2026
Tim Moore House: U.S. House ClerkNC14bought$1k–$15k7 Nov 2025filed 2 Dec 2025
Tim Moore House: U.S. House ClerkNC14bought$15k–$50k29 Oct 2025filed 12 Nov 2025

Insiders

Buy orders, 12 months0
Sale orders, 12 months1
Buyers · sellers0 · 1
WhoDidSharesTraded
Brent M. LongneckerDirectorsold8at $1.2314 Apr 2026filed 15 Apr 2026
Brent M. LongneckerDirectorsold10at $1.2314 Apr 2026filed 15 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders26+3 on the quarter
New · exited7 · 4
Reported value$118K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD FIDUCIARY TRUST COnew · filed 13 Aug 202678,104$41K+78,104
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 202660,348$31K+26,976+80.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202636,350$19K+30,400+510.9%
Engineers Gate Manager LPnew · filed 14 Aug 202620,885$11K+20,885
Mayflower Financial Advisors, LLCunchanged · filed 9 Jul 202620,000$10K00.0%
UBS Group AGadded · filed 13 Aug 20264,489$2,330+4,488+448800.0%
Tower Research Capital LLC (TRC)new · filed 11 Aug 20262,847$1,478+2,847
BARCLAYS PLCnew · filed 14 Aug 20261,578$819+1,578
JONES FINANCIAL COMPANIES LLLPreduced · filed 14 Aug 20261,208$597-897−42.6%
Cheviot Value Management, LLCunchanged · filed 6 Aug 20261,000$51900.0%
31 Dec 2023 – 30 Jun 2026
21425Dec 23Sep 24Mar 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Brent M. Longnecker Company insiderDirector · last 14 Apr 20261 · 1
Mark Stanley Berger Company insiderChief Medical Officer · last 27 Feb 20260 · 0
Ryan M. Confer Company insiderPresident, CEO and CFO · last 27 Feb 20260 · 0
Tim Moore HouseNC14 · last 5 Feb 20264 · 0
Toscano Jose Antonio Moreno Company insiderDirector · last 22 Dec 20250 · 0
William R. Wilson, Jr. Company insiderDirector · last 22 Dec 20250 · 0
John Rodney Varner Company insiderChairman, President and CEO · last 18 Feb 20243 · 0
Catherine M. Vaczy Company insiderEVP GC Chief Strategy Officer · last 21 Apr 20231 · 0
Hermant Kumar Company insiderChief Mfgr & Tech Officer · last 18 Feb 20230 · 0
Michael Thomas Redman Company insiderEVP & Chief Operating Officer · last 19 Mar 20210 · 0
David E. Friedman Company insiderDirector · last 30 Dec 20190 · 0
Robert W. Pearson Company insiderDirector · last 30 Dec 20190 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-194%
Share count trendFY 2025 · to 27 Mar 2026175%
Cash and equivalentsFY 2025 · to 31 Dec 2025$7.8M

Analyst forecasts

No analyst forecasts yet.